4r-tauopathy-spreading-comparison

4r-tauopathy-spreading-comparison

Overview

The 4-repeat (4R) tauopathies represent a spectrum of neurodegenerative disorders characterized by the predominant accumulation of 4R [tau](/proteins/tau) isoforms. While all five major 4R-tauopathies share pathological tau accumulation, they exhibit distinct regional patterns of neurodegeneration that define their clinical phenotypes. Understanding these spreading patterns is critical for differential diagnosis, biomarker development, and therapeutic intervention[@arendt2018][@baumann2022].

This page provides a comprehensive comparison of tau propagation patterns across:

• Progressive Supranuclear Palsy (PSP)
• Corticobasal Degeneration (CBD)
• Argyrophilic Grain Disease (AGD)
• Globular Glial Tauopathy (GGT)
• Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)

Comparative Summary

...

4r-tauopathy-spreading-comparison

Overview

The 4-repeat (4R) tauopathies represent a spectrum of neurodegenerative disorders characterized by the predominant accumulation of 4R [tau](/proteins/tau) isoforms. While all five major 4R-tauopathies share pathological tau accumulation, they exhibit distinct regional patterns of neurodegeneration that define their clinical phenotypes. Understanding these spreading patterns is critical for differential diagnosis, biomarker development, and therapeutic intervention[@arendt2018][@baumann2022].

This page provides a comprehensive comparison of tau propagation patterns across:

• Progressive Supranuclear Palsy (PSP)
• Corticobasal Degeneration (CBD)
• Argyrophilic Grain Disease (AGD)
• Globular Glial Tauopathy (GGT)
• Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)

Comparative Summary

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|----------|
| Primary Pattern | Subcortical-brainstem | Cortical-subcortical | Limbic | White matter-glial | Mutation-dependent |
| Tau in [Neurons](/entities/neurons) | ++ | ++ | + | + | ++ |
| Tau in Glia | ++ (tufted astrocytes) | ++ (astrocytes) | + (grains) | +++ (oligodendrocytes) | Variable |
| Asymmetry | Symmetric | Asymmetric | Symmetric | Variable | Variable |
| Staging System | NINDS-SPSP | Distribution-based | Braak-like AGD | None standardized | Mutation-specific |
| Key Regions | GP, STN, SN, midbrain | Motor [cortex](/brain-regions/cortex), putamen | Amygdala, [hippocampus](/brain-regions/hippocampus) | White matter tracts | Variable |

Progressive Supranuclear Palsy (PSP)

Spreading Pattern

PSP demonstrates a characteristic subcortical-to-cortical progression that begins in the brainstem and basal ganglia, spreading upward to involve the cortex in later stages[@williams2009][@dickson2012].

Early Stage (Braak-like I-II):

• Subthalamic nucleus (STN)
• Globus pallidus internus (GPi)
• Midbrain periaqueductal gray
• Oculomotor nuclei (riMLF, INC)

Intermediate Stage (Braak-like III-IV):

• Substantia nigra pars compacta (SNc)
• Red nucleus
• Pontine base
• Dentate nucleus of cerebellum

Late Stage (Braak-like V-VI):

• Frontal cortex
• Parietal cortex
• Motor cortex

Staging System

PSP has its own staging system based on the distribution of neurofibrillary tangles (NFTs):

• Stage 1-2: Limited to subcortical structures (GP, STN, SN)
• Stage 3-4: Brainstem involvement extends to midbrain and pons
• Stage 5-6: Cortical involvement, particularly frontal regions

Prion-Like Propagation in PSP

The propagation follows the ascending reticular activating system and basal ganglia output pathways, explaining the characteristic vertical gaze palsy and postural instability["@he2022"].

Corticobasal Degeneration (CBD)

Spreading Pattern

CBD exhibits an asymmetric cortical-subcortical pattern that typically begins in one hemisphere and spreads to the contralateral side[@kouri2014][@armstrong2013].

Early Stage:

• Primary motor cortex (Betz cells)
• Premotor cortex
• Posterior putamen
• Globus pallidus

Intermediate Stage:

• Somatosensory cortex
• Prefrontal cortex
• Substantia nigra
• Red nucleus

Late Stage:

• Contralateral motor cortex
• Temporal parietal regions
• Brainstem structures

Distribution Patterns

CBD shows significant heterogeneity with multiple patterns:

• CBS-CBD: Cortical pattern with asymmetric motor involvement
• PSD-CBD: Parkinsonism-predominant
• NFLE-CBD: Non-fluent aphasia variant

Prion-Like Propagation in CBD

CBD tau shows distinct strain characteristics from PSP, with more heterogeneous filament populations including twisted ribbons and paired helical filaments["@shi2021"].

Argyrophilic Grain Disease (AGD)

Spreading Pattern

AGD demonstrates a limbic-predominant pattern that primarily affects the medial temporal lobe and spreads through limbic circuits[@tolnay2000][@saito2004].

Early Stage (Braak AGD I-II):

• Amygdala (particularly the corticomedial nucleus)
• Entorhinal cortex
• Transentorhinal cortex

Intermediate Stage (Braak AGD III-IV):

• Hippocampus (CA1, subiculum)
• Dentate gyrus
• [Hypothalamus](/brain-regions/hypothalamus)

Late Stage (Braak AGD V-VI):

• Limbic cortex
• Orbitofrontal cortex
• Temporal pole

Staging System

AGD follows a Braak-like staging distinct from Alzheimer's disease:

• Stage I: Amygdala-predominant
• Stage II: Amygdala + entorhinal cortex
• Stage III: Add hippocampus
• Stage IV: Add hypothalamic nuclei
• Stage V-VI: Extend to isocortex

Prion-Like Propagation in AGD

AGD is characterized by argyrophilic grains - spindle-shaped tau inclusions in dendrites - which spread through the limbic system circuit[@duyckaerts2009].

Globular Glial Tauopathy (GGT)

Spreading Pattern

GGT exhibits a unique white matter-predominant pattern with 4R tau primarily accumulating in glial cells, particularly oligodendrocytes[@kovacs2011][@ferrer2018].

Early Stage:

• White matter of frontal lobes
• Deep white matter tracts
• Corpus callosum
• Internal capsule

Intermediate Stage:

• Subcortical white matter expansion
• Pyramidal tracts
• Cerebellar white matter

Late Stage:

• Extensive white matter involvement
• Gray matter infiltration
• Brainstem white matter

Key Distinguishing Feature

GGT is unique among 4R-tauopathies in that:

• Primary pathology is in glial cells (oligodendrocytes > astrocytes)
• Globular inclusions in oligodendrocytes and astrocytes
• Minimal neuronal involvement compared to other 4R-tauopathies
• White matter tract degeneration is prominent

Prion-Like Propagation in GGT

The propagation follows white matter tracts, spreading via oligodendrocyte networks and myelin-mediated transport[@lloyd2013].

Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)

Spreading Pattern

FTDP-17 shows mutation-dependent spreading patterns based on the specific MAPT mutation[@goedert2000][@rizzini2000].

Splicing Mutations (e.g., +3, +16, N279K):

• Early: Frontotemporal cortex
• Pattern resembles PSP
• Subcortical involvement prominent

Aggregation Mutations (e.g., P301L, P301S):

• Early: Frontal cortex and limbic system
• Rapid progression
• Severe neuronal loss

Missense Mutations (e.g., R406W):

• More variable pattern
• Hippocampal involvement prominent
• Resembles AD in some cases

Mutation-Specific Patterns

| Mutation Type | Primary Region | Secondary Region | Phenotype |
|--------------|---------------|------------------|-----------|
| +3 splice | Frontotemporal | Subcortical | PSP-like |
| N279K | Brainstem | Basal ganglia | PSP-like |
| P301L | Frontotemporal | Limbic | CBD-like |
| R406W | Limbic | Cortex | AD-like |

Prion-Like Propagation in FTDP-17

Comparative Propagation Mechanisms

Network-Based Spread

All 4R-tauopathies follow the principle of prion-like propagation along neural networks[@jucker2018]:

Template-Directed Misfolding: Pathological tau seeds induce misfolding of endogenous tau

Trans-synaptic Transport: Tau travels along axons to connected regions

Activity-Dependent Release: Synaptic activity promotes tau release

Recipient Neuron Uptake: Connected neurons take up extracellular tau

Strain-Specific Properties

Cryo-EM studies have revealed disease-specific tau strains[@schweighauser2020]:

| Disease | Filament Type | Core Structure | Protofilaments |
|---------|--------------|-----------------|-----------------|
| PSP | Straight filaments | 3-layer C-shaped | 2 |
| CBD | Twisted ribbons | 4-layer compact | 2-4 |
| AGD | PHFs | 3R/4R mixture | 2 |
| GGT | Straight filaments | Variable | 2 |
| FTDP-17 | Mutation-dependent | Variable | Variable |

Glial Contributions

Glial cells play different roles in each disease:

• PSP: Tufted [astrocytes](/entities/astrocytes) (highly specific marker)
• CBD: Astrocytic plaques, coiled bodies
• AGD: Argyrophilic grains in neurons and glia
• GGT: Primary oligodendroglial and astrocytic involvement
• FTDP-17: Variable glial pathology

Clinical Correlation

Regional Spreading and Symptoms

| Disease | Early Symptoms | Correlation with Spread |
|--------|---------------|------------------------|
| PSP | Vertical gaze palsy, falls | Brainstem → basal ganglia |
| CBD | Apraxia, alien limb | Motor cortex → subcortical |
| AGD | Memory loss, personality change | Limbic system involvement |
| GGT | Gait disturbance, parkinsonism | White matter → cortical |
| FTDP-17 | Behavioral change, parkinsonism | Mutation-dependent |

Biomarker Implications

Understanding spreading patterns informs biomarker development:

• CSF tau: Different isoform patterns in each disease
• PET ligands: Region-specific binding patterns
• Blood biomarkers: Disease-specific tau fragments

Clinical Translation

Clinical Trial Data

Anti-tau therapeutic trials targeting tau spreading mechanisms across 4R-tauopathies:

| Agent | Company | Target | Phase | Trial ID | Status | Notes |
|-------|---------|--------|-------|----------|--------|-------|
| E2814 | Eisai/Eldridge | p-tau217, MTBR | Phase II/III | NCT05498661 | Recruiting | DIAN-TU, PSP/CBS |
| Bepranemab | UCB | p-tau231, MTBR | Phase II | NCT04134862 | Completed | 33-58% tau PET slowing |
| Tilavonemab | Lilly | N-terminal tau | Phase II | NCT02460094 | Failed | No clinical benefit |
| Semorinemab | Roche | N-terminal tau | Phase II | NCT02880956 | Mixed | TAURIEL failed, LAURIET partial |
| Prasinezumab | Roche/Genentech | p-tau N-terminus | Phase II | NCT03100186 | Failed | No significant benefit |
| BIIB080 | Biogen | MAPT ASO | Phase II | NCT03053068 | Recruiting | Tau reduction in CSF |

Tau PET Imaging Trials:

• [18F-PM-PBB3 (APN-1607)](https://clinicaltrials.gov/NCT05498661): Tau PET ligand for 4R-tauopathies
• [18F-PI2620](https://clinicaltrials.gov/NCT04134862): Binding to 4R-tau in PSP/CBS

Biomarker Connections

CSF Biomarkers for Tau Spreading:

• p-tau181: Elevated in PSP, correlates with disease severity
• p-tau217: High specificity for 4R-tauopathies vs AD
• p-tau231: Early marker for CBD, sensitive to treatment response
• Total tau: Non-specific but indicates neuronal injury
• Neurofilament light chain (NfL): Progression marker

Imaging Biomarkers:

• Tau PET: Regional uptake patterns distinguish 4R-tauopathies
• MR volumetry: Subcortical atrophy progression
• FDG-PET: Hypometabolism patterns correlate with spreading

Blood Biomarkers:

• p-tau181 in plasma: Screening for PSP
• p-tau217: Emerging as sensitive 4R-tau marker
• NfL: General neurodegeneration marker

Patient Impact

Therapeutic Implications:

• Early intervention before extensive spreading offers best outcomes
• MTBR-targeting antibodies (E2814, bepranemab) show promise for disease modification
• Combination approaches targeting both intracellular and extracellular tau may be necessary
• Patient selection based on biomarker profile may improve trial success

Clinical Practice Integration:

• Tau PET can identify patients likely to benefit from anti-tau therapy
• CSF biomarker monitoring can track treatment response
• Early identification of spreading pattern guides prognostic counseling
• Network-based spread patterns explain variable clinical presentations

Challenges:

• Blood-brain barrier penetration for anti-tau antibodies
• Optimal timing of intervention (pre-symptomatic vs symptomatic)
• Heterogeneity of 4R-tauopathy subtypes affects treatment response
• Need for disease-specific (not AD-focused) trial designs

Related Pages

• [4R Tauopathy Molecular Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [Prion-Like Spreading in Neurodegeneration](/mechanisms/prion-like-spreading)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Progressive Supranuclear Palsy (PSP) Pathway](/mechanisms/psp-pathway)
• [CBD Pathway](/mechanisms/cbd-pathway)
• [Tau Propagation Research](/mechanisms/tau-propagation)
• [MAPT Gene](/genes/mapt)
• [Tau Protein](/proteins/tau)

See Also

• [Tau Protein](/mechanisms/tau-pathology) - 4R tau isoforms
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) - 4R-tauopathy
• [Corticobasal Syndrome](/diseases/cortico-basal-degeneration) - 4R-tauopathy
• [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles) - Tau aggregation
• [Tau Spreading Patterns](/mechanisms/tau-propagation) - Prion-like propagation

References

[Arendt T, et al., Nat Rev Dis Primers 2018 - Tauopathies (2018)](https://doi.org/10.1038/s41572-018-0029-0)

[Baumann C, et al., J Neuropathol Exp Neurol 2022 - 4R tauopathies classification (2022)](https://doi.org/10.1093/jnen/nlac019)

[Williams DR, Lees AJ, Lancet Neurology 2009 - Progressive supranuclear palsy (2009)](https://doi.org/10.1016/S1474-4422(09)70042-4)

[Dickson DW, et al., Acta Neuropathol 2012 - Neuropathology of PSP and CBD (2012)](https://doi.org/10.1007/s00401-011-0911-2)

[He Z, et al., Nat Rev Neurol 2022 - Tau propagation and Braak staging (2022)](https://doi.org/10.1038/s41582-022-00667-0)

[Kouri N, et al., Nat Rev Neurol 2014 - CBS neuropathology (2014)](https://doi.org/10.1038/nrneurol.2014.84)

[Armstrong MJ, et al., Neurology 2013 - CBD diagnostic criteria (2013)](https://pubmed.ncbi.nlm.nih.gov/23516298/)

[Shi Y, et al., Neuron 2021 - CBD tau filament structures (2021)](https://doi.org/10.1016/j.neuron.2021.09.020)

[Tolnay M, Ghetti B, Acta Neuropathol 2000 - Argyrophilic grain disease (2000)](https://doi.org/10.1007/s004010051009)

[Saito M, et al., Acta Neuropathol 2004 - AGD staging system (2004)](https://doi.org/10.1007/s00401-004-0879-4)

[Duyckaerts C, et al., Brain 2009 - AGD propagation (2009)](https://doi.org/10.1093/brain/awp053)

[Kovacs GG, et al., Brain 2011 - GGT classification (2011)](https://doi.org/10.1093/brain/awr116)

[Ferrer I, et al., Acta Neuropathol 2018 - GGT pathology (2018)](https://doi.org/10.1007/s00401-018-1870-7)

[Lloyd GM, et al., J Neurosci 2013 - Glial tau propagation (2013)](https://doi.org/10.1523/JNEUROSCI.2314-13.2013)

[Goedert M, Spillantini MG, Nat Rev Neurosci 2000 - FTDP-17 and MAPT mutations (2000)](https://doi.org/10.1038/35046076)

[Rizzini M, et al., Brain 2000 - FTDP-17 tau pathology (2000)](https://doi.org/10.1093/brain/123.8.1716)

[Jucker M, Walker LC, Nature 2018 - Self-propagation of protein aggregates (2018)](https://doi.org/10.1038/nature25479)

[Schweighauser M, et al., Nature 2020 - Tau filaments from multiple neurodegenerative diseases (2020)](https://doi.org/10.1038/s41586-020-2318-5)